Search Results - "ARRIOLA, Edurne"

Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic by Rios-Hoyo, Alejandro, Arriola, Edurne

“…Brain metastases (BMs) are the most common form of intracranial malignant neoplasms in adults, with a profound impact on quality of life and traditionally…”
Get full text

Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge by Ríos-Hoyo, Alejandro, Moliner, Laura, Arriola, Edurne

“…EGFR-mutated tumors represent a significant percentage of non-small cell lung cancer. Despite the increasing use of osimertinib, a treatment that has…”
Get full text

Targeting oncogenic ALK: a promising strategy for cancer treatment by Grande, Enrique, Bolós, María-Victoria, Arriola, Edurne

“…Recently, the anaplastic lymphoma kinase (ALK) has been found to be altered in several solid and hematologic tumors. Novel drugs targeting this tyrosine kinase…”
Get full text

Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples by Casadevall, David, Clavé, Sergi, Taus, Álvaro, Hardy-Werbin, Max, Rocha, Pedro, Lorenzo, Marta, Menéndez, Silvia, Salido, Marta, Albanell, Joan, Pijuan, Lara, Arriola, Edurne

“…Expression of programmed death-ligand 1 (PD-L1) in tumor cells and infiltrating immune cells was retrospectively analyzed in a cohort of surgically-treated…”
Get full text

Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study by Garon, Edward B., Winfree, Katherine B., Molife, Cliff, Cui, Zhanglin Lin, Arriola, Edurne, Levy, Benjamin, Mekhail, Tarek, Pérol, Maurice

“…Purpose In REVEL, patients with advanced non-small-cell lung cancer (aNSCLC) and patients with increased tumor aggressiveness (rapid disease progression (RDP),…”
Get full text

CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous‐cell and adenocarcinoma patients by Clavé, Sergi, Pijuan, Lara, Casadevall, David, Taus, Álvaro, Gimeno, Javier, Hernández‐Llodrà, Silvia, Rodríguez‐Rivera, María, Lorenzo, Marta, Menéndez, Silvia, Albanell, Joan, Espinet, Blanca, Arriola, Edurne, Salido, Marta

“…Aims CD274 (PDL1) and JAK2 (9p24.1) gene amplifications have been recently described in pulmonary carcinomas in association with programmed death‐ligand 1…”
Get full text

CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer by Olingy, Claire, Alimadadi, Ahmad, Araujo, Daniel J, Barry, David, Gutierrez, Norma A, Werbin, Max Hardy, Arriola, Edurne, Patel, Sandip Pravin, Ottensmeier, Christian H, Dinh, Huy Q, Hedrick, Catherine C

“…Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related deaths globally. Immune checkpoint blockade (ICB) has transformed cancer medicine,…”
Get full text

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry by Conde, Esther, Suárez-Gauthier, Ana, Benito, Amparo, Garrido, Pilar, García-Campelo, Rosario, Biscuola, Michele, Paz-Ares, Luis, Hardisson, David, de Castro, Javier, Camacho, M Carmen, Rodriguez-Abreu, Delvys, Abdulkader, Ihab, Ramirez, Josep, Reguart, Noemí, Salido, Marta, Pijuán, Lara, Arriola, Edurne, Sanz, Julián, Folgueras, Victoria, Villanueva, Noemí, Gómez-Román, Javier, Hidalgo, Manuel, López-Ríos, Fernando

“…Based on the excellent results of the clinical trials with ALK-inhibitors, the importance of accurately identifying ALK positive lung cancer has never been…”
Get full text

Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control by Arriola, Edurne, Wheater, Matthew, Krishnan, Radhika, Smart, James, Foria, Vipul, Ottensmeier, Christian

“…Ipilimumab is a standard therapy for advanced melanoma. Severe immune related adverse events occur in up to 30% of patients and require treatment with…”
Get full text

Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer by Salido, Marta, Pijuan, Lara, Martínez-Avilés, Luz, Galván, Ana B, Cañadas, Israel, Rovira, Ana, Zanui, Montserrat, Martínez, Alejandro, Longarón, Raquel, Sole, Francisco, Serrano, Sergio, Bellosillo, Beatriz, Wynes, Murry W, Albanell, Joan, Hirsch, Fred R, Arriola, Edurne

“…Translocation of the anaplastic lymphoma kinase (ALK) gene is involved in the tumorigenesis of a subset of non-small cell lung carcinomas (NSCLCs) and…”
Get more information

Management of crizotinib therapy for ALK -rearranged non-small cell lung carcinoma: An expert consensus by Cappuzzo, Federico, Moro-Sibilot, Denis, Gautschi, Oliver, Boleti, Ekaterini, Felip, Enriqueta, Groen, Harry J.M, Germonpré, Paul, Meldgaard, Peter, Arriola, Edurne, Steele, Nicola, Fox, Jesme, Schnell, Patrick, Engelsberg, Arne, Wolf, Jürgen

“…Highlights • Crizotinib is a standard of care for ALK-positive lung cancer. • Crizotinib-associated AEs are mostly mild to moderate in severity. • Appropriate…”
Get full text

Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer by Clavé, Sergi, Jackson, Jennifer B, Salido, Marta, Kames, Jacob, Gerding, Kelly M R, Verner, Ellen L, Kong, Eric F, Weingartner, Elizabeth, Gibert, Joan, Hardy-Werbin, Max, Rocha, Pedro, Riera, Xènia, Torres, Erica, Hernandez, James, Cerqueira, Gustavo, Nichol, Donna, Simmons, John, Taus, Álvaro, Pijuan, Lara, Bellosillo, Beatriz, Arriola, Edurne

“…Next-generation sequencing (NGS) is currently widely used for biomarker studies and molecular profiling to identify concurrent alterations that can lead to the…”
Get full text

Diffuse dermal mucinosis secondary to colony‐stimulating factor 1 receptor monoclonal antibody treatment: A novel and peculiar drug‐induced diffuse cutaneous mucinosis by Olmos‐Alpiste, Ferran, Segura, Sonia, Tomás‐Velázquez, Alejandra, Aguado, Leyre, España, Agustín, Arriola, Edurne, Martín‐Algarra, Salvador, Barranco, Carlos, Lloreta, Josep, Pujol, Ramon M.

“…Colony‐stimulating factor 1 receptor (CSF1R) inhibitors represent a new class of immune‐modulatory drugs, mostly investigated in clinical trials in different…”
Get full text

Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines by Arriola, Edurne, Marchio, Caterina, Tan, David SP, Drury, Suzanne C, Lambros, Maryou B, Natrajan, Rachael, Rodriguez-Pinilla, Socorro Maria, Mackay, Alan, Tamber, Narinder, Fenwick, Kerry, Jones, Chris, Dowsett, Mitch, Ashworth, Alan, Reis-Filho, Jorge S

“…HER2 and TOP2A are targets for the therapeutic agents trastuzumab and anthracyclines and are frequently amplified in breast cancers. The aims of this study…”
Get full text

Prognostic Value of Clinical Staging According to TNM in Patients With SCLC: A Real-World Surveillance Epidemiology and End-Results Database Analysis by Arriola, Edurne, Trigo, José Manuel, Sánchez-Gastaldo, Amparo, Navarro, Alejandro, Perez, Coral, Crama, Leonardo, Ponce-Aix, Santiago

“…SCLC is one of the most lethal malignancies. Classically, staging has been performed using a dual classification distinguishing limited from the extensive…”
Get full text

Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer by ARRIOLA, Edurne, RODRIGUEZ-PINILLA, Socorro Maria, LAMBROS, Maryou B. K, JONES, Robin L, JAMES, Michelle, SAVAGE, Kay, SMITH, Ian E, DOWSETT, Mitch, REIS-FILHO, Jorge S

“…TOP2A gene encodes topoisomerase II alpha, the direct molecular target of anthracyclines. This gene is frequently coamplified with HER2. The aims of this study…”
Get full text

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain by Arriola, Edurne, García Gómez, Ramón, Diz, Pilar, Majem, Margarita, Martínez Aguillo, Maite, Valdivia, Javier, Paredes, Alfredo, Sánchez-Torres, José Miguel, Peralta Muñoz, Sergio, Barneto, Isidoro, Gutierrez, Vanesa, Andrade Santiago, Jesús Manuel, Aparisi, Francisco, Isla, Dolores, Ponce, Santiago, Vicente Baz, David, Artal, Angel, Amador, Mariluz, Provencio, Mariano

“…Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several…”
Get full text

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer by Hardy-Werbin, Max, Rocha, Pedro, Arpi, Oriol, Taus, Álvaro, Nonell, Lara, Durán, Xavier, Villanueva, Xavier, Joseph-Pietras, Deborah, Nolan, Luke, Danson, Sarah, Griffiths, Richard, Lopez-Botet, Miguel, Rovira, Ana, Albanell, Joan, Ottensmeier, Christian, Arriola, Edurne

“…Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently…”
Get full text

RET Fusion Testing in Patients With NSCLC: The RETING Study by Conde, Esther, Hernandez, Susana, Rodriguez Carrillo, Jose Luis, Martinez, Rebeca, Alonso, Marta, Curto, Daniel, Jimenez, Beatriz, Caminoa, Alejandra, Benito, Amparo, Garrido, Pilar, Clave, Sergi, Arriola, Edurne, Esteban-Rodriguez, Isabel, De Castro, Javier, Sansano, Irene, Felip, Enriqueta, Rojo, Federico, Dómine, Manuel, Abdulkader, Ihab, Garcia-Gonzalez, Jorge, Teixido, Cristina, Reguart, Noemi, Compañ, Desamparados, Insa, Amelia, Mancheño, Nuria, Palanca, Sarai, Juan-Vidal, Oscar, Baixeras, Nuria, Nadal, Ernest, Cebollero, Maria, Calles, Antonio, Martin, Paloma, Salas, Clara, Provencio, Mariano, Aranda, Ignacio, Massuti, Bartomeu, Lopez-Vilaro, Laura, Majem, Margarita, Paz-Ares, Luis, Lopez-Rios, Fernando

“…RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of RET fusions remains a difficult…”
Get full text

Multiple Brain Pseudoprogression in a Patient With NSCLC Treated With Pembrolizumab by Moliner, Laura, Capellades, Jaume, Taus, Álvaro, Arriola, Edurne

Get full text